{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:44:45Z","timestamp":1762253085154},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"50","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,8,27]]},"DOI":"10.18632\/oncotarget.27098","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T14:36:18Z","timestamp":1566916578000},"page":"5136-5151","source":"Crossref","is-referenced-by-count":7,"title":["Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma"],"prefix":"10.18632","volume":"10","author":[{"given":"Lu\u00eds Alberto","family":"de P\u00e1dua Covas Lage","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemotherapy and Cell Therapy, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9bora","family":"Levy","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Genetics and Molecular Hematology (LIM-31), Universidade de S\u00e3o Paulo, S\u00e3oPaulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via Dias","family":"Xavier","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hemotherapy, Faculdade de Medicina da Universidade de Bras\u00edlia, Bras\u00edlia, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego C\u00e2ndido","family":"Reis","sequence":"additional","affiliation":[{"name":"Medical Sciences Discipline, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"de Oliveira Costa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hemotherapy Discipline, Faculdade de Ci\u00eancias M\u00e9dicas de Santos\/Centro Universit\u00e1rio Lus\u00edada, Santos, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Castro","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Departamento of Pathology, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy and Cell Therapy, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"},{"name":"President Funda\u00e7\u00e3o Pr\u00f3-Sangue, Churchill Hospital, Oxford University, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cl\u00e1udia Nogueira","family":"Zerbini","sequence":"additional","affiliation":[{"name":"Departamento of Pathology, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy and Cell Therapy, Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"1","first-page":"3909","article-title":"The non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","year":"1997","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"9","author":"Weisenburger","year":"1998","journal-title":"Ann Oncol"},{"key":"3","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Vardiman","year":"2016"},{"key":"4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"5","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Weisenburger","year":"2008","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/leu.2008.320","article-title":"Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas","volume":"23","author":"Dogan","year":"2009","journal-title":"Leukemia"},{"key":"7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas. Annual clinical updates in hematological malignancies: a continuing medical education series","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"key":"8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3109\/10428194.2013.858154","article-title":"The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma","volume":"55","author":"Savage","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V83.5.1165.1165","article-title":"Prognostic factors in aggressive non-Hodgkin\u2019s lymphoma: who has \u201chigh-risk\u201d disease?","volume":"83","author":"Shipp","year":"1994","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"L\u00f3pez-Guillermo","year":"2011","journal-title":"Ann Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","article-title":"Identification of a proliferative signature related to survival in nodal peripheral T-cell lymphomas","volume":"25","author":"Martinez-Delgado","year":"2007","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","article-title":"Etoposide: four decades of development of a topoisomerase II inhibitor","volume":"34","author":"Hande","year":"1998","journal-title":"Eur J Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"key":"14","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/bloodadvances.2017010819","article-title":"Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma","volume":"1","author":"Koh","year":"2017","journal-title":"Blood Adv"},{"key":"15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cytogfr.2008.01.006","article-title":"IkappaB kinase beta (IKKbeta\/IKK2\/IKBKB)\u2014a key molecule in signaling to the transcription factor NF-kappaB","volume":"19","author":"Birbach","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.18632\/oncotarget.109","article-title":"A critical role for the NFkB pathway in multiple myeloma","volume":"1","author":"Kuehl","year":"2010","journal-title":"Oncotarget"},{"key":"17","first-page":"162","article-title":"Regulation of NF-kB in multiple myeloma: therapeutic implications","volume":"2","author":"Berenson","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"19","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1038\/sj.onc.1209982","article-title":"Inhibitors of NF-kappaB signaling: 785 and counting","volume":"25","author":"Herscovitch","year":"2006","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Ben\u00ectez, The Spanish Cooperative Group for the study of T-cell lymphomas. Differential expression of NF-kappa B pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Ben\u00edtez","year":"2005","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"Helleday","year":"2005","journal-title":"Nat Cell Biol"},{"key":"22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Lukas","year":"2003","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-15-2477","article-title":"Proteasomal inhibition by ixazomib induces CHK1 and MYC-dependent cell death in T-cell and Hodgkin lymphoma","volume":"76","author":"Evens","year":"2016","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","article-title":"Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells","volume":"17","author":"Nilsson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/ajh.24895","article-title":"A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas","volume":"92","author":"Wilcox","year":"2017","journal-title":"Am J Hematol"},{"key":"26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/bjc.2017.398","article-title":"How the evolution of multicellularity set the stage for cancer","volume":"118","author":"Goode","year":"2018","journal-title":"Br J Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/bjc.2014.576","article-title":"Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response","volume":"112","author":"Rakha","year":"2015","journal-title":"Br J Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10654-005-2028-1","article-title":"Molecular bias","volume":"20","author":"Ioannidis","year":"2005","journal-title":"Eur J Epidemiol"},{"key":"29","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"\u00d8stenstad","year":"2012","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Weisenburger","year":"1999","journal-title":"Blood"},{"key":"31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/jcp.53.6.445","article-title":"ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination","volume":"53","author":"Meijer","year":"2000","journal-title":"J Clin Pathol"},{"key":"32","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Aiello","year":"1999","journal-title":"Blood"},{"key":"33","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype","volume":"96","author":"Ogura","year":"2000","journal-title":"Blood"},{"key":"34","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials","volume":"30","author":"Delsol","year":"2012","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"Gaulard","year":"2007","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","article-title":"Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation","volume":"67","author":"Zupo","year":"2007","journal-title":"Cancer Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/labinvest.3700145","article-title":"Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression","volume":"84","author":"Janin","year":"2004","journal-title":"Lab Invest"},{"key":"38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Nabhan","year":"2015","journal-title":"Br J Haematol"},{"key":"39","first-page":"1860","article-title":"Report of comitee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Tubiana","year":"1971","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Lister","year":"2014","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Falini","year":"2000","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.prp.2015.11.008","article-title":"From RNA isolation to microarray analysis: comparison of methods in FFPE tissues","volume":"212","author":"\u00d6zda\u011f","year":"2016","journal-title":"Pathol Res Pract"},{"key":"43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Wittwer","year":"2009","journal-title":"Clin Chem"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T15:11:59Z","timestamp":1664205119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":43,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,8,27]]}},"alternative-id":["27098","31497245"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27098","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]}}}